New drug shows promise for bulging eyes in thyroid disease
NCT ID NCT06226545
First seen Mar 21, 2026 · Last updated Jun 16, 2026 · Updated 15 times
Summary
This study tested a new medicine called LASN01 in 41 adults with thyroid eye disease, a condition that causes eye bulging and discomfort. The goal was to see if LASN01 could safely reduce eye bulging compared to a placebo. Participants received either LASN01 or a dummy treatment by IV, and researchers measured changes in eye position and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EYE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 101
San Diego, California, 92093, United States
-
Site 103
Miami, Florida, 33136, United States
-
Site 104
Houston, Texas, 77401, United States
-
Site 105
Palo Alto, California, 94303, United States
-
Site 106
Houston, Texas, 77030, United States
-
Site 108
Livonia, Michigan, 48152, United States
-
Site 109
Seattle, Washington, 98104, United States
-
Site 110
Wilmington, North Carolina, 28403, United States
-
Site 111
Beverly Hills, California, 90210, United States
-
Site 112
Las Vegas, Nevada, 89144, United States
-
Site 201
London, EC1V 2PD, United Kingdom
-
Site 204
Newcastle upon Tyne, NE1 4LP, United Kingdom
-
Site 206
London, NW1 5QH, United Kingdom
-
Site 301
Seville, 41009, Spain
-
Site 302
Córdoba, 14012, Spain
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.